User login
Article Type
Changed
Tue, 12/13/2016 - 12:08
Display Headline
Sitagliptin's Safety; New Option Approved for Hospital-Acquired Pneumonia; FDA Approves First Nonhormonal Drug for Menopause Symptoms
Article PDF
Issue
Federal Practitioner - 30(9)
Publications
Topics
Page Number
41-42
Legacy Keywords
sitagliptin, dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor, cardiovascular risk factors, Staphylococcus aureus, S aureus, methicillin-resistant staphylococcus aureus, Assessment of Telavancin for Treatment of Hospital Acquired Pneumonia, streptococcus pneumoniae, menopause, vasomotor symptoms, hot flashes, paroxetine
Sections
Article PDF
Article PDF
Issue
Federal Practitioner - 30(9)
Issue
Federal Practitioner - 30(9)
Page Number
41-42
Page Number
41-42
Publications
Publications
Topics
Article Type
Display Headline
Sitagliptin's Safety; New Option Approved for Hospital-Acquired Pneumonia; FDA Approves First Nonhormonal Drug for Menopause Symptoms
Display Headline
Sitagliptin's Safety; New Option Approved for Hospital-Acquired Pneumonia; FDA Approves First Nonhormonal Drug for Menopause Symptoms
Legacy Keywords
sitagliptin, dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor, cardiovascular risk factors, Staphylococcus aureus, S aureus, methicillin-resistant staphylococcus aureus, Assessment of Telavancin for Treatment of Hospital Acquired Pneumonia, streptococcus pneumoniae, menopause, vasomotor symptoms, hot flashes, paroxetine
Legacy Keywords
sitagliptin, dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor, cardiovascular risk factors, Staphylococcus aureus, S aureus, methicillin-resistant staphylococcus aureus, Assessment of Telavancin for Treatment of Hospital Acquired Pneumonia, streptococcus pneumoniae, menopause, vasomotor symptoms, hot flashes, paroxetine
Sections
Article Source
PURLs Copyright
Inside the Article
Article PDF Media
Document